# WEARE JUISTIN VIENT SECHE TASTEOLOGY

Investor Presentation | September 2022




### **Cautionary Statement Regarding Forward-Looking Statements**

This presentation contains certain "forward-looking information" within the meaning of applicable Canadian securities legislation as well as statements that may constitute "forward-looking statements" within the meaning of within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our strategy, future operations, intended expansion of our retail operations and production capacity, intended expansion of our cultivation facilities, future financial position, projected costs, prospects, plans and objectives of management, including without limitation Q4 2022 annualized guidance, are forward-looking statements. These forward-looking statements are based on Jushi's current expectations and beliefs concerning future developments and their potential effects. As a result, actual results could differ materially from those expressed by such forward-looking statements and such statements should not be relied upon. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as "plans," "expects" or "does not expect," "is expected," "budget," "scheduled," "estimates," "intends," "anticipates" or "does not anticipate," or "believes," or variations of such words and phrases or may contain statements that certain actions, events or results "may," "could," "might" or "will be taken," "will continue," "will occur" or "will be achieved". The forward-looking information and forward-looking statements contained herein may include but are not limited to, information concerning the expectations regarding Jushi, or the ability of Jushi to successfully achieve business objectives, and expectations for other economic, business, and/or competitive factors. Many factors could cause actual future events to differ materially from the forwardlooking statements in this presentation, including risks related to the ability of Jushi to successfully and/or timely achieve business objectives, including with regulatory bodies, employees, suppliers, customers and competitors; changes in general economic, business and political conditions, including changes in the financial markets; changes in applicable laws; and compliance with extensive government regulation, as well as other risks, uncertainties and other cautionary statements in the Company's public filings with the applicable securities regulatory authorities on the SEC's website at www.sec.gov and on SEDAR at www.sedar.com. Should one or more of these risks, uncertainties or other factors materialize, or should assumptions underlying the forwardlooking information or statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated, or expected.

Although the Company believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking information and statements are reasonable, undue reliance should not be placed on such information and statements, and no assurance or guarantee can be given that such forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information and statements. The forward-looking information and forward-looking statements contained in this presentation are made as of the date of this presentation, and the Company does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws. All subsequent written and oral forward-looking information and statements attributable to the Company or persons acting on its behalf is expressly qualified in its entirety by this notice.

# **Cannabis Industry Opportunity**






Legal U.S. Recreational Cannabis Market

Legal U.S. Medical Cannabis Market

(1) Cowen Ahead of the Curve Series, Cowen Research (Published March 2022)
 (2) Statista: US Prescription Drug Market
 (3) Statista: US Alcoholic Drink Market

### MSO Industry Growth & Valuation Vs. Other Industries



Industry Sales CAGR ('19 to '22)

MSO valuation is in stark contrast with growth rates compared to other industries<sup>(1)</sup>

## What Sets Jushi Apart?



Jushi's highly concentrated position in limited license states with favorable regulatory developments and a best-in-class M&A track record sets us apart.

Industry Leading Organic Revenue and Adj. EBITDA<sup>(1)</sup> Margin Growth, Driven by Retail and Wholesale Expansion and Vertical Integration

Highly Concentrated Position in Markets w/ Favorable Regulatory Developments

Highly Accretive Acquisition Opportunities in Existing Markets

Best-in-Class M&A Track Record


**Solid Liquidity Position** 

**Industry Leading Online Platform** 

**Early Focus on "ESG" Principles** 

(1) See Adjusted EBITDA Reconciliation Table on page 18 for more details, as well as disclaimers on page 19 the Adjusted EBITDA definition


### Industry Leading Revenue and Adj. EBITDA Margin Growth, Driven by Retail and Wholesale Expansion and Vertical Integration




\*See Adjusted EBITDA Reconciliation Table on page 17 for more details as well as disclaimers on page 19 for how Adjusted EBITDA is defined. \*\*Adjusted EBITDA for 2020 and 2021 was calculated on a Non-IFRS basis. Q4 2022 Annualized Adjusted EBITDA is presented on a Non-GAAP basis..

# Highly Concentrated Position in Markets with Favorable Regulatory Developments

Emerging Markets	Regulatory Status	Jushi Assets
Pennsylvania	Mature medical program / Planning for adult-use	<ul> <li>Vertically Integrated</li> <li>18 medical dispensaries</li> <li>123k sq. ft. facility (add'l expansion potential)</li> </ul>
Virginia	Early medical program / adult-use legislation passed	<ul> <li>Vertically Integrated</li> <li>4 medical dispensaries open (total of 6 planned)</li> <li>93k sq. ft. facility (add'l expansion potential)</li> </ul>
Ohio**	Early medical program / Planning for adult- use	<ul> <li>Vertically Integrated</li> <li>1 awarded provisional medical retail license</li> <li>8k sq. ft. processing facility</li> <li>10k sq. ft. grow facility (add'l expansion potential)</li> </ul>





# Highly Accretive Acquisition Opportunities in Existing Markets

NV IL \$1.1B' \$2.5B'	ОН МА \$1.7В'	
	\$1.6B* MAL IL OH	
CA	CO* VA	
Vertically-Integrated Operations	Non-Vertical Operations 🛨 Jushi Office Location	

\*Source: Headset; estimated market size by 2025 \*\*Upon regulatory approval, Beyond Hello™ Cincinnati store is expected to open in Q4 2022.

# Best-in-Class M&A Track Record



State	Price Paid	Close Date	Recent Market Deals
Pennsylvania			
Retail - 12 Licences (FBS - PA)	\$63 million	July 2019	Three operational dispensaries (\$90mm)
Retail – 3 Licenses (Agape)	\$12 million	June 2020	<ul> <li>Three operational dispensaries (\$120mm w/ earn-out)</li> <li>Three operational dispensaries (\$35mm w/ earn-out)</li> </ul>
Retail – 3 Licenses (PDS)	\$5 million	December 2020	<ul> <li>Three operational dispensaries (\$60mm)</li> <li>Three operational dispensaries (\$120mm)</li> </ul>
Retail Total	\$80 million		
Grower Processor (PAMS)	\$37 million	August 2020	<ul> <li>35K sq. ft. GP, expanding to 90k sq. ft. (\$93mm w/ earnout)</li> <li>143k sq. ft. GP, plus licenses for six dispensaries (\$64mm)</li> <li>52k sq. ft. GP, expanding to 104k sq. ft., plus licenses for six dispensaries (\$80mm)</li> </ul>
TOTAL	\$117 million		
Virginia			
Vertical License – 1 License Dalitso	\$33 million	September 2019	• One vertically integrated license (\$83mm, plus earn-out)
Illinois			
Retail – 4 Licenses (TGS)	\$12.5 million	January 2020	<ul> <li>Four operational dispensaries, 2 licenses (\$155mm)</li> <li>Two operational dispensaries (\$43mm)</li> <li>One operational dispensary, one license (\$28mm)</li> </ul>
Massachusetts			
Retail – 2 licenses & GP Facility (Nature's Remedy)	\$79.6 million (w/earn-out)*	September 2021	<ul> <li>GP and three operational dispensaries (\$158mm w/ earn- out)</li> </ul>

\*Nature's Remedy's total consideration is \$79.6 million, based on an upfront payment of \$69.6 million using a \$1.50 share price, plus a \$10 million earn-out

## **Solid Liquidity Position**



# Industry-Leading Online Platform

Percent of Total<br/>Sales OnlineOnline<br/>Conversion RateAverage<br/>Cart Size~60%20%\$89Q2 2022Q2 2022Q2 2022

Driving Online Revenue Growth Through Best-In-Class Customer Experience



# Early Focus on Environmental, Social and Governance ("ESG") Principles

### **Environmental**

- Focus on environmentally sustainable construction Culver City, CA
- Increasing use of organic packaging materials
- Work with domestic vendors who use green manufacturing and sustainable sourcing practices
- Leverage Business Energy Efficiency Program as available in states, to minimize electricity consumption in our facilities



E

### Social

- Maintain leadership position in workforce diversity
- Established Diversity, Equity, and Inclusion (DEI) team focused on empowering employees and improving the representation of people and ideas
- Actively working with states to create legislation that will advance social equity ownership within the cannabis space

### Governance

- Diversity at the Board of Director level: two of the five members of the board are diverse (ethnicity & gender)
- Compliance Hotline (whistleblower program)

# Appendix

# **Store Opening Schedule**



State	<b>Store Count</b> (As of Q1'22)	Q2'22	Q3'22	Q4'22	Store Count (As of 12/31/22)	<b>Targeted</b> Store Count (As of 12/31/23) <sup>(1)</sup>
Pennsylvania	18	-	-	_	18	18
Illinois	4	-	-	-	4	10
Virginia	2	-	2	1	5	6
California	2	1	-	-	3	4
Massachusetts	2	-	-	-	2	3
Ohio	-	-	-	1	1	5
Nevada	1	3	_	-	4	4
TOTAL	29	4	2	2	37	50

# Bolstered Cultivation and Processing Capabilities



~73k sq. ft. of canopy

~41k lbs. of annual biomass capacity Year-End 2022


~330k sq. ft. of cultivation and processing capabilities

~100k sq. ft. of canopy

~59k lbs. of annual biomass capacity

# Expansion in high-growth, limited license states, including:

- Pennsylvania (Scranton)
- Virginia (Manassas)
- Massachusetts (Lakeville)
- Nevada (North Las Vegas)
- Ohio (Toledo & Columbus)
- Illinois (TBD)



# **Bolstered Cultivation and Processing Capabilities**

State	Total Building (sq ft)	Canopy (sq ft)	Annual Biomass Capacity (Ibs)	Estimated Completion Date
Pennsylvania – Scranton Facility				
Existing Facility*	81,000	~16,000	~8,000	Completed
Phase 1 Expansion	~123,000	~27,000	~15,000	Completed
Phase 2 Expansion	~210,000	~107,000	~60,000	Future**
Virginia – Manassas Facility				

Existing Facility	30,000*	~2,700	~1,700	Completed
Phase 1 Expansion	93,000	~13,000	~9,000	Completed
Phase 2 Expansion	~195,000	~63,000	~41,000	Future**
Phase 3 Expansion	~263,000	~118,000	~79,000	Future**

Disclaimers

### JUSHI HOLDINGS INC. Reconciliation of Non-GAAP Financial Measures

### EBITDA, Adjusted EBITDA and Adjusted Gross Profit

In addition to providing financial measurements based on GAAP, the Company provides additional financial metrics that are not prepared in accordance with GAAP. Management uses non-GAAP financial measures, in addition to GAAP financial measures, to understand and compare operating results across accounting periods, for financial and operational decision making, for planning and forecasting purposes and to evaluate the Company's financial performance. These non-GAAP financial measures are EBITDA, Adjusted EBITDA and Adjusted Gross Profit (defined below). Management believes that these non-GAAP financial measures reflect the Company's ongoing business in a manner that allows for meaningful comparisons and analysis of trends in the business, as they facilitate comparing financial results across accounting periods and to those of peer companies. As there are no standardized methods of calculating these non-GAAP measures, the Company's methods may differ from those used by others, and accordingly, the use of these measures may not be directly comparable to similar measures used by others, thus limiting their usefulness. Accordingly, these non-GAAP measures are intended to provide additional information and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with GAAP.

EBITDA, Adjusted EBITDA and Adjusted Gross Profit are financial measures that are not defined under GAAP. Management defines EBITDA as net income (loss), or "earnings", before interest, income taxes, depreciation and amortization. Management defines Adjusted EBITDA as EBITDA before: (i) non-cash share-based compensation expense and other one-time charges; (ii) inventory-related adjustments; (iii) fair value changes in derivatives; (iv) other income/expense items (xiii) transaction costs; and (v) start-up costs. These financial measures are metrics that have been adjusted from the GAAP net income (loss) measure in an effort to provide readers with a normalized metric in making comparisons more meaningful across the cannabis industry, as well as to remove non-recurring, irregular and one-time items that may otherwise distort the GAAP net income measure. Other companies in the Corporation's industry may calculate this measure differently, limiting their usefulness as comparative measures. Management defines Adjusted Gross Profit as gross profit, as reported, adjusted to exclude certain inventory-related adjustments and start-up costs (within cost of goods sold).

# **Adjusted EBITDA Reconciliation**

### JUSHI HOLDINGS INC. UNAUDITED RECONCILIATION OF NET LOSS TO ADJUSTED EBITDA (in thousands of U.S. dollars)

	ree Months ed June 30, 2022	Three Months Ended March 31, 2022	Three Months Ended June 30, 2021
NET INCOME (LOSS) <sup>(1)</sup>	\$ 12,066	\$ (19,757)	\$ 3,437
Income tax expense	7,710	5,051	6,711
Interest expense, net	10,947	10,116	6,868
Depreciation and amortization <sup>(2)</sup>	 4,355	3,248	1,478
EBITDA (Non-GAAP)	\$ 35,078	\$ (1,342)	\$ 18,494
Non-cash share-based compensation and other one-time charges <sup>(3)</sup>	4,800	7,159	4,573
Inventory-related adjustments <sup>(4)</sup>	436	3,742	
Fair value changes in derivatives	(42,572)	(14,309)	(21,098)
Other (income) expense items <sup>(5)</sup>	(1,096)	380	558
Start-up costs <sup>(6)</sup>	991	2,715	1,199
Transaction costs <sup>(7)</sup>	 2,885	780	870
Adjusted EBITDA (Non-GAAP)	\$ 522	\$ (875)	\$ 4,596

(1) Net income (loss) includes amounts attributable to non-controlling interests.

(2) Includes amounts that are included in cost of goods sold and in operating expenses.

(3) Includes: (i) non-cash share-based compensation expense for the period; and (ii) severance costs.

(4) Includes: (i) inventory step-up on business combinations; (ii) inventory recall reserves; and (iii) reserves for discontinued products. The inventory step-up on business combinations relate to the fair value write-up on inventory acquired on the business acquisition date and then sold subsequent to the acquisition date. The inventory recall reserves relate to the estimated impact of the Pennsylvania Department of Health recall and ban of vape products containing certain cannabis concentrates. The ban was lifted in June 2022.

(5) Includes: (i) remeasurement of contingent consideration related to acquisitions; (ii) losses (gains) on investments and financial assets; and (iii) losses (gains) on legal settlements.

(6) Expansion and start-up costs incurred in order to prepare a location for its intended use. Start-up costs are expensed as incurred and are not indicative of ongoing operations of each new location.

(7) Transaction costs include: (i) registration statement costs such as professional fees and other costs relating to our SEC registration; and (ii) acquisition and deal costs.

#### Disclaimers

# •

### NO OFFERS

This presentation does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of securities of the Company in any jurisdiction in which an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

The securities of the Company described herein have not been and will not be registered under the United States federal or state securities laws and may not be offered or sold in the United States, or to, or for the account or benefit of, "U.S. Persons" as such term is defined in Regulation S under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), unless an exemption from registration is available. Prospective investors will be required to represent, among other things, that they meet the requirements of an available exemption from the registration requirements of the U.S. Securities Act and are familiar with and understand the terms of the offering and have all requisite authority to make such investment.

IN MAKING AN INVESTMENT DECISION, INVESTORS MUST RELY ON THEIR OWN EXAMINATION OF THE COMPANY AND THE TERMS OF THE OFFERING, INCLUDING THE MERITS AND RISKS INVOLVED. THE SECURITIES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE SECURITIES AND EXCHANGE COMMISSION OR BY ANY STATE SECURITIES COMMISSION OR REGULATORY AUTHORITY, NOR HAVE ANY OF THE FOREGOING AUTHORITIES OR ANY CANADIAN PROVINCIAL SECURITIES REGULATOR PASSED ON THE ACCURACY OR ADEQUACY OF THIS PRESENTATION. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.

### THIRD PARTY INFORMATION

This presentation may include market and industry data which was obtained from various publicly available sources and other sources believed by the Company to be true. Although the Company believes it to be reliable, the Company has not independently verified any of the data from third-party sources referred to in this presentation or analyzed or verified the underlying reports relied upon or referred to by such sources, or ascertained the underlying assumptions relied upon by such sources. The Company does not make any representation as to the accuracy of such information.

#### TARGET AUDIENCE

This presentation is only addressed to those persons, which have been explicitly determined by the Company as recipients. The Company did not and will not authorize any third parties to distribute this presentation or make it available to persons not determined by the Company or to the public. Any unauthorized distribution or disclosure will constitute an infringement of the concluded non-disclosure agreement and the Company reserves the right to take further legal action in such cases. No action has been (or will be) taken by the Company that would permit the possession or distribution of this presentation. Persons into whose possession this presentation may come are required to inform themselves of and observe any corresponding restrictions. The Company does not accept any responsibility for any violation by any person of any such restrictions.

### REGULATORY

Potential investors are aware that the cannabis market is highly regulated, and that various permits and authorizations are necessary for the import, distribution, sale or other business activities related to medicinal cannabis. The respective regulations can be subject to change, which might affect the permits required. This presentation does not intend to advertise the products of the Company. Any reference to the products serves only the information of potential investors and shall not incite the purchase of the products.

### TAXATION

Prospective investors should be aware that the purchase of securities of the Company or any entity related thereto may have tax consequences both in Canada and the United States. Each prospective investor is strongly encouraged to consult its own tax advisor concerning any purchase of securities of the Company or any entity related thereto and the holding and disposition of any such securities. This presentation does not address the tax consequences of the purchase, ownership or disposition of any such securities.

### COPYRIGHT

All brands and trademarks mentioned in this presentation and possibly protected by third parties are subject without restriction to the provisions of the applicable trademark law and the ownership rights of the respective registered owners. The mere fact that a trademark is mentioned should not lead to the conclusion that it is not protected by the rights of third parties. The copyright for published objects created by the Company remains solely with the Company. Any duplication or use of objects such as diagrams, sounds or texts in other electronic or printed publications is not permitted without the Company's agreement.

### CURRENCY

All references to \$ or "dollar" in this presentation are references to USD, unless otherwise indicated.